AIM ImmunoTech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

by Barry101 | Mar 31, 2022 | Press Release, Uncategorized

– Year marked by continued execution across clinical development programs and the continued establishment of a growing body of positive data with Ampligen® in multiple high-value indications – Company expected to continue advancing oncology-focused...

AIM ImmunoTech Announces Abstract Accepted for Presentation at 15th Annual IHPBA World Congress

by Barry101 | Mar 28, 2022 | Press Release, Uncategorized

OCALA, Fla., March 28, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...

AIM ImmunoTech Announces Abstract Entitled, Negative Impact of Paclitaxel on Human Breast Tumor Microenvironment and Its Reversal by the Combination of Interferon-α with TLR3 Agonist Rintatolimod, (Ampligen®), Accepted for Poster Presentation by Roswell Park Comprehensive Cancer Center at the AACR 2022 Annual Meeting

by Barry101 | Mar 24, 2022 | Press Release, Uncategorized

OCALA, Fla., March 24, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...

AIM ImmunoTech to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

by Barry101 | Mar 23, 2022 | Press Release, Uncategorized

Company to participate in live panel, “Pancreatic Cancer: Turning the Tide for One of the Most Challenging Indications in Oncology,” on Monday, March 28th at 12:00 PM ETOCALA, Fla., March 23, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM)...

AIM ImmunoTech Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer

by Barry101 | Mar 16, 2022 | Press Release, Uncategorized

Data seen to date indicates that Ampligen® (rintatolimod) could be a potential effective maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer In a single-center named patient program, treatment with Ampligen following...

AIM ImmunoTech Announces Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the AACR 2022 Annual Meeting

by Barry101 | Mar 9, 2022 | Press Release, Uncategorized

OCALA, Fla., March 09, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...